Latest News & Features
Americas
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success. 3 November 2014
Asia-Pacific
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore. 3 November 2014
Europe
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK. 3 November 2014
Americas
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications. 3 November 2014
Europe
Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy. 3 November 2014
Asia
A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj. 29 October 2014
Biotechnology
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS. 29 October 2014
Americas
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does. 29 October 2014
Americas
Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions. 30 September 2014
Americas
The Bay Area of California has one
of the greatest concentrations of life
sciences companies in the world,
but its biotech community is being
threatened by the seemingly
unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler,
vice chair, of the new North Bay
Life Science Alliance to find out
how it plans to strengthen the network in the area. 30 September 2014